National Quality Measures Clearinghouse | Measures by Topic: Prostatic Neoplasms

National Quality Measures Clearinghouse | Measures by Topic: Prostatic Neoplasms

Measures by Topic

Disease/Condition > Diseases (1537) > Neoplasms (179) > Neoplasms by Site (113) > Urogenital Neoplasms (14) > Genital Neoplasms, Male (5) >

Prostatic Neoplasms (5)

Search WithinSearch within:    Go

Sort results by:  Relevance (what's this?)    Publication date

Filter results by:   All Years  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1997  1990 

1-5 of 5
1.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling on, at a minimum, the following treatment options for clinically localized disease prior to initiation of treatment: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy. 2012 Sep. NQMC:008653 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
2.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist). 2012 Sep. NQMC:008654 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
3.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment. 2012 Sep. NQMC:008650 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
4.   Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer. 2012 Sep. NQMC:008652 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected
5.   Prostate cancer: percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score. 2012 Sep. NQMC:008651 American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s)